On August 21, Hims & Hers Health Inc. rose 5.16% in regular trading, trading at $33.5/share, with turnover of $123 million. The stock extended its multi-day rebound driven by management's continued aggressive pushback against the FTC lawsuit filed on July 30.

On the news front, CEO Andrew Dudum has repeatedly addressed FTC allegations that the company shared user health data with Meta and Snap, engaged in billing irregularities, and created subscription cancellation barriers. Dudum characterized the charges as stemming from misunderstanding of the company's business model, emphasizing that Hims & Hers is a \"positive disruptor\" focused on expanding healthcare accessibility. The company stated that the lawsuit ignores substantial evidence provided during nearly three years of investigation.

Supporting the rebound, Needham raised its price target to $42 and Morgan Stanley lifted its target to $28 from $21 while maintaining an Equalweight rating. Since the July 30 selloff of over 12% triggered by the FTC lawsuit announcement, HIMS has posted consecutive days of recovery, reflecting easing investor concerns amid sustained management engagement.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)